Yiteng Zhang

Yiteng Zhang

Auto-generated profile, based on publicly available information

Yiteng Zhang

Department of Ophthalmology West China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2026 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
YTYunhan Tao
Yunhan Tao
YZYiteng Zhang
Yiteng Zhang
WXWei Xu
Wei Xu
GLGuina Liu
Guina Liu
HLHongtao Liu
Hongtao Liu
Diabetic macular edema (DME) remains a leading cause of vision loss in the working-age population, yet its management is undergoing a fundamental paradigm shift from high-frequency anti-VEGF monotherapy toward more durable and multi-mechanism therapeutic strategies. This narrative review provides an up-to-date overview of the pharmacological landscape of DME as of 2025, synthesizing evidence from pivotal clinical trials, recent regulatory approvals, and available real-world outcomes. We examine the transition toward injection-sparing approaches and discuss the clinical rationale for targeting alternative biological pathways beyond VEGF inhibition, including angiopoietin-2 (eg, faricimab), the plasma kallikrein-kinin system, and tyrosine kinase-mediated signaling. Collectively, emerging evidence suggests that the future management of DME will be defined by a paradigm shift toward injection-sparing, multi-pathway therapeutic strategies, extending beyond short-term fluid suppression toward a more personalized, precision-medicine framework that prioritizes long-term durability, safety, and functional outcomes.